An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics

Abigail A. Zalenski1,2, Shubhra Majumder1,3, Kuntal De1,4 & Monica Venere1,5

KIF11 is a homotetrameric kinesin that peaks in protein expression during mitosis. It is a known mitotic regulator, and it is well-described that KIF11 is necessary for the formation and maintenance of the bipolar spindle. However, there has been a growing appreciation for non-mitotic roles for KIF11. KIF11 has been shown to function in such processes as axon growth and microtubule polymerization. We previously demonstrated that there is an interphase pool of KIF11 present in glioblastoma cancer stem cells that drives tumor cell invasion. Here, we identified a previously unknown association between KIF11 and primary cilia. We confirmed that KIF11 localized to the basal bodies of primary cilia in multiple cell types, including neoplastic and non-neoplastic cells. Further, we determined that KIF11 has a role in regulating cilia dynamics. Upon the reduction of KIF11 expression, the number of ciliated cells in asynchronously growing populations was significantly increased. We rescued this effect by the addition of exogenous KIF11. Lastly, we found that depleting KIF11 resulted in an increase in cilium length and an attenuation in the kinetics of cilia disassembly. These findings establish a previously unknown link between KIF11 and the dynamics of primary cilia and further support non-mitotic functions for this kinesin.

KIF11, also known as Eg5 and Kinesin-5, is a mitotic kinesin that is responsible for forming and maintaining the bipolar spindle. KIF11 has primarily been studied for its mitotic role, and is thought to be mostly degraded after mitosis1–4. However, there is a growing body of work that implicates KIF11 in other, non-mitotic cell processes. KIF11 has been demonstrated to have microtubule polymerase activity, as well as to control axon growth7,8. It has also been shown to mediate centrosome migration after mitosis and move Golgi material3,9. Additionally, we have previously studied a non-mitotic role for KIF11 in the context of glioblastoma (GBM). We identified that in the GBM cancer stem cell subpopulation, KIF11 is highly overexpressed throughout the cell cycle due to attenuated protein degradation4,10. Cancer stem cells are found in many tumor types, and are characterized as being radio and chemo resistant. We found that this interphase pool of KIF11 was responsible for driving tumor cell invasion and process formation1.

In addition to these reported non-mitotic roles of KIF11, there are two patient populations that have reported mutations in the KIF11 gene. The associated diseases are known as microcephaly with or without chorioretinopathy, mental retardation, and lymphedema (MCLMR) and familial exudative vitreoretinopathy (FEVR), with the latter having reported KIF11 mutations in only a subset of the patients. The mutations are found throughout the gene, and a given mutation is not typically seen in more than one patient unless inherited11–16. Importantly, all reported patient mutations are heterozygous, with many of the mutations predicted to lead to haploinsufficiency.
Results
KIF11 localizes to the basal body of primary cilia in GBM cells. Our previous work with KIF11 demonstrated that the protein is overexpressed throughout the cell cycle in patient-derived GBM cells. Additionally, it has been demonstrated that primary cilia can be found in patient-derived GBM samples, but the role of these cilia is somewhat disputed. Because of the elevated levels of KIF11, and the presence, albeit not well understood, of primary cilia in GBM tumorspheres, we sought to understand if KIF11 was associated with these primary cilia. To answer this question, we grew patient-derived GBM (08-387) tumorspheres in suspension, then fixed the spheres and immunolabeled for KIF11 and the primary cilia markers Arl13b and Cep135 to mark both the axoneme and basal body/centrosome, respectively. Confocal imaging of cilia in tumorspheres revealed that KIF11 localized near the basal bodies of primary cilia (Fig. 1a). Because the role of primary cilia in GBM tumorspheres is not well understood, we also aimed to further characterize the ciliated cells in these samples. We first immunolabeled cells for Ki67 (a marker for proliferating cells), Arl13b, and pericentrin (a marker for pericentriolar material). Imaging of these tumorspheres demonstrated that primary cilia could be found on both Ki67 negative and positive cells (Fig. 1b). This finding is interesting, as primary cilia are most often found on quiescent cells, and hence would not stain positively for Ki67. However, there are examples where cilia are present on proliferative cell populations, such as on neural progenitors in fetal and postnatal proliferative zones, as well as in cancer cells. Our data agrees with previous reports that cilia can be present on proliferating cancer cells. We also labeled tumorspheres for Sox2 (a marker for cancer stem cells), Arl13b, and pericentrin to determine if cilia are present on cancer stem cells. We found that almost all ciliated cells were Sox2 positive, indicating a possible association between primary cilia and the cancer stem cell population (Fig. 1c). These data demonstrate that KIF11 is localized at the basal bodies of primary cilia in GBM tumorspheres. Furthermore, they support previous reports that primary cilia in GBM tumorspheres have been identified on Ki67 positive cells.

KIF11 localizes to the basal body of primary cilia in non-neoplastic cells and associates with ciliary proteins. As primary cilia in tumorspheres are not well understood and may be differently regulated than primary cilia in non-neoplastic cells, we next wanted to investigate whether KIF11 also localized to basal bodies of primary cilia on non-neoplastic cells. To address this question, we collected a serum starved population of immortalized retinal pigmented epithelial cells (hTERF-RPE1 or RPE1 cells), and immunolabeled for KIF11, Arl13b, and Cep135. We immunolabeled these antibodies simultaneously and each antibody individually to validate KIF11 localization distinctly at the basal body region of primary cilia. Serum starvation in RPE1 led to quiescent/ G0-synchronized cells, which were used to maximize the number of cells with primary cilia in our samples. Akin to what we identified in GBM cancer stem cells, we found that KIF11 was also localized near the basal body of primary cilia in RPE1 cells (Fig. 2a,b). We also used another cell model, immortalized human neural progenitor cells, to examine KIF11 and primary cilia. Again, using immunofluorescence, we determined that KIF11 localized near the basal body of these primary cilia as well (Fig. 2c,d). Lastly, we collected G0-synchronized RPE1 cells for proteomic analysis to determine if KIF11 interacted with any cilia-associated proteins. We immunoprecipitated KIF11 from our samples, and then performed proteomic analyses to identify any interacting partners. We identified over 30 cilia-associated proteins within the interactome for KIF11 in G0-synchronized RPE1 cells; 14 of these proteins were identified in replicate screens (Table 1, bold indicates proteins identified in replicate screens, non-bolded identified in one screen). These results demonstrate that KIF11 is localized to primary cilia in multiple cell types and may directly or indirectly interact with cilia-associated proteins, suggesting that KIF11 may play a role in the regulation of cilia dynamics in normal cells.

KIF11 depletion alters cilia dynamics and length. Having identified that KIF11 localized at the basal body of primary cilia and interacts with ciliary proteins, we next sought to investigate if KIF11 had a role in regulating primary cilia. To answer this question, we used two siRNAs designed against KIF11 (siKIF11-1 and siKIF11-2), as well as a control siRNA (siControl) with depletion of KIF11 confirmed at the protein level by immunoblotting (Supplementary Fig. 1a,b). We treated asynchronously growing RPE1 cells with either siControl, or one of the two siKIF11s. siRNAs to KIF11 were titrated to an amount that did not impact the ability
of the cells to go through the cell cycle, as demonstrated by equal numbers of EdU positive cells in siControl
and siKIF11 groups (Supplementary Fig. 1c). 72 h post siRNA treatment, cells were fixed and immunofluores-
cence was performed to examine primary cilia. KIF11 depletion led to a significant increase in the number of
primary ciliated RPE1 cells over siControl-treated cells (Fig. 3a). Importantly, this shift towards increased ciliation
was not merely due to all of the cells becoming quiescent, as evidenced by the incorporation of EdU into an equal
number of cells as those treated with siControl (Supplementary Fig. 1c). Since a decrease in KIF11 via siRNA
carried an increase in the number of ciliated RPE1 cells over siControl-treated cells (Fig. 3a). Importantly, this shift towards increased ciliation was not merely due to all of the cells becoming quiescent, as evidenced by the incorporation of EdU into an equal number of cells as those treated with siControl (Supplementary Fig. 1c). Since a decrease in KIF11 via siRNA caused an increase in the number of ciliated RPE1 cells, we also overexpressed GFP and GFP-KIF11 in asynchronous RPE1 cells to determine if this would also impact the number of primary cilia. Both 24 and 48 h after GFP or GFP-KIF11 transfection into RPE1 cells, we did not see any difference in the percent of ciliated cells between the two groups (Supplementary Fig. 1d). We then co-transfected siKIF11-1 with either GFP alone, or an siRNA-resistant, GFP-tagged KIF11 to determine if KIF11 was sufficient to rescue this change in the percentage of cili-
ated cells. When GFP-KIF11 was transfected into the cells, the phenotype of increased cilia was partially rescued in positively-transfected cells (Fig. 3b). We also determined that depleting KIF11 increased the length of primary
cilia over siControl-treated cells (Fig. 3c). The length of primary cilia is tightly regulated, and changes in length could indicate changes in cilia-mediated signaling39,40. To further explore how reducing KIF11 impacted primary cilia dynamics, we studied the impact on serum-induced primary cilia disassembly. When RPE1 cells are serum-starved, approximately 80% of the cells will become quiescent and form cilia. In this experiment, RPE1 cells were serum-starved for 48 h, and then serum was added back to the cells to induce cilium disassembly and cell cycle reentry. Cells were fixed for immunofluorescence at the time of serum addition (0 h), as well as 9 h later, when cilia in more than 50% of the cells should have been disassembling. At 9 h post-serum addition, there were significantly more ciliated cells remaining when cells were treated with siKIF11 (Fig. 3d). Together, these data demonstrate, for the first time, that a reduction in KIF11 is enough to alter primary cilia dynamics and presence on a cell, as well as primary cilia length. Furthermore, we have shown that this reduction in KIF11 is permissible in the context of mitosis, but there is a separate, primary cilium-specific effect that cannot function normally with the decrease in protein.

Heterozygous KIF11 alters cilia dynamics and length. Because MCLMR and FEVR patients are reported to have a mutation in only one allele of KIF11, we next created two heterozygous CRISPR/Cas9 clonal lines of RPE1 cells to experimentally represent this genetic state (crKIF11-1 and crKIF11-2). Gene editing via CRISPR/Cas9 more closely reflects the patient mutational state than RNA interference via siRNA, and hence is critical for evaluating the impact of reduced KIF11 on primary cilia dynamics. Depletion of KIF11 was confirmed by immunoblotting (Supplementary Fig. 2a–c). Asynchronously growing wild type RPE1 cells, as well as asynchronous crKIF11-1 and crKIF11-2 cells were collected for immunofluorescence. Cells were fixed for immunofluorescence at the time of serum addition (0 h), as well as 9 h later, when cilia in more than 50% of the cells should have been disassembling. At 9 h post-serum addition, there were significantly more ciliated cells remaining when cells were treated with siKIF11 (Fig. 3d). Together, these data demonstrate, for the first time, that a reduction in KIF11 is enough to alter primary cilia dynamics and presence on a cell, as well as primary cilia length. Furthermore, we have shown that this reduction in KIF11 is permissible in the context of mitosis, but there is a separate, primary cilium-specific effect that cannot function normally with the decrease in protein.

Heterozygous KIF11 alters cilia dynamics and length. Because MCLMR and FEVR patients are reported to have a mutation in only one allele of KIF11, we next created two heterozygous CRISPR/Cas9 clonal lines of RPE1 cells to experimentally represent this genetic state (crKIF11-1 and crKIF11-2). Gene editing via CRISPR/Cas9 more closely reflects the patient mutational state than RNA interference via siRNA, and hence is critical for evaluating the impact of reduced KIF11 on primary cilia dynamics. When RPE1 cells are serum-starved, approximately 80% of the cells will become quiescent and form cilia. In this experiment, RPE1 cells were serum-starved for 48 h, and then serum was added back to the cells to induce cilium disassembly and cell cycle reentry. Cells were fixed for immunofluorescence at the time of serum addition (0 h), as well as 9 h later, when cilia in more than 50% of the cells should have been disassembling. At 9 h post-serum addition, there were significantly more ciliated cells remaining when cells were treated with siKIF11 (Fig. 3d). Together, these data demonstrate, for the first time, that a reduction in KIF11 is enough to alter primary cilia dynamics and presence on a cell, as well as primary cilia length. Furthermore, we have shown that this reduction in KIF11 is permissible in the context of mitosis, but there is a separate, primary cilium-specific effect that cannot function normally with the decrease in protein.

**Table 1. KIF11 associated primary cilia proteins.**

| KIF11 interactor | Cilia-related protein function | References |
|------------------|-------------------------------|------------|
| KIF5B/Kinesin-1  | Associated with regulating cilia length through interaction with BBSome | 26,27      |
| HSPA8            | Chaperone, associated with photoreceptors | 26,27      |
| SPTAN1           | Cilia associated, knockdown decreases number of cilia | 27,28      |
| FLNA             | Ciliogenesis and basal body positioning; associates with Meckelin (gene causing MKS) | 26,39      |
| IPO5             | Enriched in cilia | 27,29      |
| MYH10            | Responsible for centriole migration during formation of primary cilia | 27,30,31,42|
| SF3B2            | Identified in primary cilia interaction screen | 27         |
| PKM              | Identified in primary cilia interaction screen | 27         |
| SF3A1            | Identified in primary cilia interaction screen | 27         |
| HSP90AB1         | Identified in primary cilia interaction screen | 27         |
| EFTUD2           | Identified in primary cilia interaction screen | 27         |
| EEF1A1           | Identified in primary cilia interaction screen | 27         |
| ATP2A2           | Identified in primary cilia interaction screen | 27         |
| CLTC             | Identified in primary cilia interaction screen | 27         |
| SEPT2            | Associated with cilia length modulation | 27,32,34   |
| SEPT9            | Associated with cilia length modulation | 27,32,34   |
| DCTN1            | Associated with ciliogenesis | 27,35      |
| EXOC4            | Centrosome component | 27,36      |
| ANXA1            | Enriched in cilia | 27,37      |
| ATP2B4           | Localizes to/associated with primary cilia | 27         |
| GSN              | Promotes cilia formation | 27         |
| CTNNB1           | Wnt pathway effector | 27,38      |
| HSP90B1          | Identified in primary cilia interaction screen | 27         |
| HK1              | Identified in primary cilia interaction screen | 27         |
| TUBA1B           | Identified in primary cilia interaction screen | 27         |
| HSP90AA1         | Identified in primary cilia interaction screen | 27         |
| TUBB4B           | Identified in primary cilia interaction screen | 27         |
| DNM2             | Identified in primary cilia interaction screen | 27         |
| CASK             | Identified in primary cilia interaction screen | 27         |
| TUBB             | Identified in primary cilia interaction screen | 27         |
| TUBA1A           | Identified in primary cilia interaction screen | 27         |

**Table 1. KIF11 associated primary cilia proteins.**

Because MCLMR and FEVR patients are reported to have a mutation in only one allele of *KIF11*, we next created two heterozygous CRISPR/Cas9 clonal lines of RPE1 cells to experimentally represent this genetic state (crKIF11-1 and crKIF11-2). Gene editing via CRISPR/Cas9 more closely reflects the patient mutational state than RNA interference via siRNA, and hence is critical for evaluating the impact of reduced KIF11 on primary cilia dynamics. When RPE1 cells are serum-starved, approximately 80% of the cells will become quiescent and form cilia. In this experiment, RPE1 cells were serum-starved for 48 h, and then serum was added back to the cells to induce cilium disassembly and cell cycle reentry. Cells were fixed for immunofluorescence at the time of serum addition (0 h), as well as 9 h later, when cilia in more than 50% of the cells should have been disassembling. At 9 h post-serum addition, there were significantly more ciliated cells remaining when cells were treated with siKIF11 (Fig. 3d). Together, these data demonstrate, for the first time, that a reduction in KIF11 is enough to alter primary cilia dynamics and presence on a cell, as well as primary cilia length. Furthermore, we have shown that this reduction in KIF11 is permissible in the context of mitosis, but there is a separate, primary cilium-specific effect that cannot function normally with the decrease in protein.
area to be covered by receptors. Therefore, we hypothesize that the increase in cilium length brought on by ciliation could lead to aberrant signaling (Fig. 5a). In addition to the number of ciliated cells impacting signaling, there could be an increase in cilia at a time when cells should not assemble cilia. Ultimately, such a loss of suppression of ciliation could lead to aberrant signaling (Fig. 5b). Further, we propose that these impacts on signaling patterns might explain some of the phenotypes seen in patients with MCLMR and FEVR. Future studies could ascertain the role of KIF11 in primary cilia-mediated signaling by examining downstream gene expression in pathways such as sonic hedgehog and Wnt.

Our study is the first to establish a role between KIF11 and regulation of primary cilia, but further exploration will be required to understand the mechanism of how KIF11 impacts primary cilia dynamics. It is worth noting that multiple other mitotic kinesins have been shown to regulate primary cilia, independent of their role in mitosis. KIF14, a kinesin involved in bipolar spindle formation, has recently been shown to also play a role in basal body and primary cilia formation. Upon KIF14 depletion, cilium elongation and assembly is altered, as well as hedgehog signaling, through an association with Aurora Kinase A\(^{51}\). KIF2, KIF3, and KIF13 have all been shown to function in mitosis, as well as to have critical primary cilia regulatory roles\(^{52,53}\). Additionally, Mps1, a kinase essential for mitosis, has been shown to coordinate with VDAC3 to negatively regulate the inappropriate formation of primary cilia through accumulation at the centrosomes\(^{54}\). Perhaps KIF11 is acting in a similar way to one or more of these proteins, and is coordinating with other primary cilia proteins. The cell cycle and primary cilia formation are inextricably linked so it stands to reason, and has been experimentally demonstrated, that many of the proteins involved in the cell cycle might also be critical for the proper formation and regulation of primary cilia. Our data are the first step in exploring KIF11 in this context, and future studies should elucidate the mechanism for this previously unknown role for KIF11.

**Discussion**

Our results are the first to demonstrate that KIF11 is localized at the basal body of primary cilia in multiple cell types, including neoplasic and non-neoplasic cells. Additionally, we have shown a previously unknown ability for KIF11 to regulate primary cilia dynamics. Typically, primary cilia are present when cells are quiescent and are only found on a small percentage of asynchronously growing cells, which are likely in early G1 phase\(^{23}\). Our results indicate that by depleting KIF11, we are able to shift this percentage of ciliated cells, implicating KIF11 as a regulator of cilia dynamics. KIF11’s role as a primary cilia-regulator is further supported by our finding that transfection of KIF11 partially rescues the increase in ciliation in asynchronous cells. Further, in heterozygous KIF11 RPE1 cells, we see the same increase in ciliation. An increase in the amount of ciliated cells is important, as primary cilia regulate the careful balance in signaling patterns required for homeostasis\(^{42–45}\). Primary cilia are covered in receptors for different pathways, and oftentimes, these receptors are not expressed anywhere else on the cell\(^{46–48}\). Therefore, careful timing of when primary cilia (and therefore, their receptors) are present is critical for proper pathway activity. For example, during neurodevelopment the expansion of the neural progenitor pool relies upon cilia-mediated sonic hedgehog signaling\(^{45}\). If there are too many cilia, signaling could be disrupted or aberrant, and conversely, if cells are not ciliated, signaling will not occur. This leads us to consider a model where KIF11 is necessary for proper expression of primary cilia, and may suppress ciliation in inappropriate contexts. Furthermore, if KIF11 is depleted or mutated in a biological system, we hypothesize that there could be an increase in cilia at a time when cells should not assemble cilia. Ultimately, such a loss of suppression of ciliation could lead to aberrant signaling (Fig. 5a). In addition to the number of ciliated cells impacting signaling, the length of the cilium is also important when discussing relative signaling activity. Change in cilium length has been shown to function in mitosis, as well as to have critical primary cilia regulatory roles\(^{52,53}\). Additionally, Mps1, a kinase essential for mitosis, has been shown to coordinate with VDAC3 to negatively regulate the inappropriate formation of primary cilia through accumulation at the centrosomes\(^{54}\). Perhaps KIF11 is acting in a similar way to one or more of these proteins, and is coordinating with other primary cilia proteins. The cell cycle and primary cilia formation are inextricably linked so it stands to reason, and has been experimentally demonstrated, that many of the proteins involved in the cell cycle might also be critical for the proper formation and regulation of primary cilia. Our data are the first step in exploring KIF11 in this context, and future studies should elucidate the mechanism for this previously unknown role for KIF11.

![Figure 3](https://doi.org/10.1038/s41598-020-70787-4)
Methods

Cell culture. Human GBM specimen (GBM 08-387; kindly provided by Dr. Jeremy Rich, UC San Diego) was originally isolated from a tumor resection in accordance with approved institutional review board protocols at Duke University and the Cleveland Clinic Lerner Research Institute. GBM 08-387 was maintained through subcutaneous xenografts in the flanks of athymic nude mice or NOD scid gamma mice under approved institutional protocols and in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Tumors were dissociated using a Papain Dissociation System (Worthington Biochemical). Cells were cultured in Neurobasal Media (Gibco) with B-27 supplement (without vitamin A; Gibco), basic fibroblast growth factor (10 ng/mL; Gibco), EGF (10 ng/mL; Gibco), l-glutamine (2 mmol/L; Gibco), and sodium pyruvate (1 mmol/L; Gibco) and grown in suspension. Immortalized retinal pigmented epithelial cells (RPE1) were commercially obtained (ATCC) and grown in DMEM/F12 (Gibco) with fetal bovine serum (Gibco). For serum starvation experiments, RPE1 cells were grown in DMEM/F12 without the addition of fetal bovine serum. Immortalized human neural
progenitors were obtained commercially (SigmaMillipore) and were grown in ReNcell neural stem cell maintenance media (SigmaMillipore) with basic fibroblast growth factor (10 ng/mL; Gibco) and EGF (10 ng/mL; Gibco). All cells were cultured at 37 °C at 5% CO₂. For cell counting before each experiment, a single-cell suspension was achieved using TrypLE (Gibco). Mycoplasma testing was done quarterly (LookOut Mycoplasma PCR Detection Kit; Sigma-Aldrich) and cell line verification was done annually (microsatellite genotyping; OSUCCC Genomics Shared Resource).

**Immunofluorescence.** Tumorspheres were fixed in 100% methanol and immunolabeled with combinations of the following primary antibodies: anti-Arl13b (Proteintech; 17711-1-AP; rabbit; 1:250), anti-Cep135 (Abcam; ab75005; rabbit; 1:1,000), anti-KIF11 (BD Biosciences; 611,186; mouse; 1:500), anti-pericentrin (Covance; PRB-432C; rabbit; 1:500), anti-Ki67 (Cell Signaling; 9,449; mouse; 1:800), or anti-Sox2 (R&D Systems; MAB2018; rabbit; 1:1,000) overnight at 4 °C. Primary labeling was followed by secondary detection with Alexa Fluor 488 and 568 (Invitrogen; 1:20,000). Secondary antibodies (LI-COR Biosciences, 926-68070, goat α-mouse, 1:20,000) were incubated in PBS, and immunolabeled with anti-Arl13b, anti-Cep135, anti-acetylated tubulin (Sigma; T 6,793; mouse; 1:2,000), anti-KIF11 for 1 h at room temperature, followed by secondary detection with Alexa Fluor 488, 568, and 647 (Invitrogen; A32731, A-11031, A32733; goat α-rabbit, goat α-mouse, goat α-rabbit; 1:500 or 1:1,000) for 1 h at room temperature. Nuclei were counterstained with Hoechst. Coverslips were then mounted onto slides using Fluoromount-G (SouthernBiotech). Images were taken using a Zeiss LSM 800 confocal microscope or a Leica DM5500B upright epifluorescence 171 microscope.

**KIF11 depletion.** For siRNA experiments, RPE1 cells were plated at 100,000 cells per well of a 6 well plate containing glass coverslips. 24 h after plating, cells were transfected with either siControl, siKIF11-1 (both to a final concentration of 5 nM), or siKIF11-2 (to a final concentration of 250 pM) using RNAiMax transfection reagent (Thermo Fisher) according to the RNAiMax protocol. Media was changed every 24 h, and cells were continuously monitored to ensure no gross mitotic arrest or cell death. At 72 h post siRNA transfection, cells were fixed with methanol for immunofluorescence or harvested for immunoblotting to ensure KIF11 depletion. siRNAs were obtained from Integrated DNA Technologies IDT (siKIF11-1: AGT TTT AGAGACATCCTGACTTT GATAGCTAAATTTAA, siKIF11-2: GGC AAA AAC CTG AAT AGT CTG TTT A). For rescue experiments, 24 h after siRNA addition, 0.5–1 µg of pEGFP or pEGFP-KIF11 DNA plus 1–1.5 µg pcDNA3.1 carrier DNA were transfected to the cells using Fugene 6 transfection reagent and associated protocol. Media was changed 24 h later, and cells were collected 24 h after media change. CRISPR clones were generated by using the ribonucleoprotein (RNP) method. This method refers to the use of a guide RNA which is complexed to purified Cas9 protein. All products used to generate CRISPR clones were obtained from IDT. crRNA and tracrRNA were complexed together to create the gRNA; the crRNA is KIF11-specific and was designed by IDT (GGT GGA ATTTA CCAGGCAA). The gRNA and purified Cas9 were combined to create the RNP complexes, and were delivered to RPE1 cells via transfection with CRISPRmax and Cas9 Plus transfection reagents. After transfection with RNPs, cells were incubated for 48 h. After 48 h, cells were plated sparsely (20 cells per well of a 6 well plate). Cells were monitored over the next two weeks to watch for clonal outgrowth. Individual colonies were then harvested and moved into their own well of a 96 well plate. These colonies were expanded for approximately 2 more weeks, at which point cells were harvested for immunoblotting to detect levels of KIF11 and expanded for experimental use.

**GFP and GFP-KIF11 overexpression.** RPE1 cells were plated at 100,000 cells per well of a six well plate containing glass coverslips. Twenty-four hours later, 0.5 µg of pEGFP or pEGFP-KIF11 DNA plus 1.5 µg pcDNA3.1 carrier DNA were transfected to the cells using Fugene 6 transfection reagent and associated protocol. Cells were either collected and fixed at 24 h or had media changed at 24 h and were collected at 48 h.

**Cilium quantification and measurement.** Percentage of ciliated cells was quantified by imaging experimental cells, and counting the total number of cells and the number of ciliated cells. Percentages were calculated by number of ciliated cells/total number of cells. When GFP transfection was used, only GFP-positive cells were used in the calculation of ciliated cells/total cells. Cilia length was measured for siKIF11 experiments with the Zen (blue edition) software compatible with Zeiss microscopes. Cilia were traced with the measurement tool to calculate their length in microns. The same measurement was conducted in the crKIF11 cells, but using the LAS AF software, compatible with Leica microscopes.

**Protein extraction and immunoblotting.** Whole cell extracts were made using a 50 mM Tris pH 8.0, 120 mM NaCl, 0.5% NP-40 lysis solution supplemented with protease and phosphatase inhibitors (Roche). Samples were run on 10% SDS-PAGE gels and transferred to PVDF membranes (Millipore Corp.). The membranes were blocked with 5% (w/v) dry milk in TBS-Tween-20 (TBST; 0.1–0.2% v/v) and probed with primary antibodies overnight at 4 °C (anti-KIF11, BD Biosciences, 611,186, mouse, 1:3,000; anti-β-actin, Sigma, A1978, mouse, 1:20,000). Secondary antibodies (LI-COR Biosciences, 926-68070, goat α-mouse, 1:20,000) were incubated in TBST plus 0.01–0.02% SDS and visualized with the LI-COR Odyssey near infrared imaging system.
**Immunoprecipitation.** Immunoprecipitations were carried out using Dynabeads Protein G (Invitrogen). Briefly, 25 µl of beads were incubated with 3 µg of KIF11 antibody (Novus; NB500-181; rabbit) for 30 min at room temperature followed by washes and then an overnight incubation at 4 °C with 25 mg of G0 synchronized RPE1 whole cell extract. For analysis of proteins off beads, immunoprecipitated proteins were released from the beads by boiling in Laemmli 2X concentrate sample buffer (Sigma).

**Samples for LC–MS/MS analysis.** For “on-bead” analysis, KIF11 from G0 synchronized RPE1 was immunoprecipitated as described above with resulting immunoprecipitated protein taken on beads for processing by the Proteomics Shared Resource at The Ohio State University Comprehensive Cancer Center for protein quantification and identification of protein interactors. For KIF11 that was boiled off beads, samples were resolved on 4–20% Mini-PROTEAN TGX gel precast gels (Bio-Rad Laboratories, Inc.) and visualized with GelCode Blue Stain Reagent as per manufacturer instructions (ThermoFisher Scientific). The KIF11 band was then cut from the gel and processed by the Lerner Research Institute Mass Spectrometry Laboratory for Protein Sequencing for proteomic analysis and identification of interacting proteins.

**Cell growth.** Cell growth was monitored after depletion of KIF11 by EdU labeling and by Incucyte ZOOM live-cell imaging. EdU labeling was accomplished by exposing cells to a 4-h pulse of EdU prior to harvesting the cells at the end of the experiment. Cells that were exposed to EdU were then fixed in 100% methanol, permeabilized in PBS-Triton X-100 (0.2% vol/vol), and labeled with the reagents and protocol associated with the Click-iT EdU Cell Proliferation Kit for Imaging (Thermo Fisher). Nuclei were counterstained with Hoechst. Coverslips were then mounted onto slides using Fluoromount-G (SouthernBiotech). Images were taken using a Zeiss LSM 800 confocal microscope. To track cells via Incucyte live-cell imaging, 50,000 WT RPE1 or crKIF11 cells were plated in wells of a 6 well plate and placed on the Incucyte. Cell confluence was used as a measure of growth, and was monitored over 40 h. Multiple areas of each well were monitored.

**Statistical analyses.** Statistical significance was calculated with GraphPad Prism Software using a Student’s t-test or 2-way ANOVA with Sidak’s post-test (GraphPad Software, Inc.).

Received: 15 May 2020; Accepted: 31 July 2020
Published online: 18 August 2020

**References**

1. Waitzman, J. S. & Rice, S. E. Mechanism and regulation of kinesin-5, an essential motor for the mitotic spindle. *Biol. Cell.* **106**(1), 1–12 (2014).
2. Valentine, M. T. et al. Individual dimers of the mitotic kinesin motor Eg5 step processively and support substantial loads in vitro. *Nat. Cell Biol.* **8**(5), 470–476 (2006).
3. Whitehead, C. M. & Rattner, J. B. Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle. *J. Cell Biol.* **111**(Pt 17), 2551–2561 (1998).
4. Venere, M. et al. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. *Sci. Transl. Med.* **7**(304), 304–343 (2015).
5. Eguren, M. et al. A synthetic lethal interaction between APC/C and topoisomerase poisons uncovered by proteomic screens. *Cell Rep.* **4**(6), 670–683 (2014).
6. Drosopoulos, K. et al. APC/C is an essential regulator of centrosome clustering. *Nat. Commun.* **5**, 3686 (2014).
7. Chen, T. & Hancock, W. O. Kinesin-5 is a microtubule polymerase. *Nat. Commun.* **6**, 8160 (2015).
8. Myers, K. A. & Baas, P. W. Kinesin-5 regulates the growth of the axon by acting as a brake on its microtubule array. *J. Cell Biol.* **178**(6), 1081–1091 (2007).
9. Wakana, Y. et al. Kinesin-5/Eg5 is important for transport of CARTS from the trans-Golgi network to the cell surface. *J. Cell Biol.* **202**(2), 241–250 (2013).
10. De, K. et al. Hyperphosphorylation of CDH1 in glioblastoma cancer stem cells attenuates APC/C(CDH1/CDC20) compromises viability. *Mol. Cancer Res.* **17**(7), 1519–1530 (2019).
11. Jones, G. E. et al. Microcephaly with or without chorioretinopathy, lymphoedema, or mental retardation (MCLMR): review of the phenotype associated with KIF11 mutations. *Eur. J. Hum. Genet.* **22**(7), 881–887 (2014).
12. Li, J. K. et al. Identification of novel KIF11 mutations in patients with familial exudative vitreoretinopathy and a phenotypic analysis. *Sci. Rep.* **6**, 26564 (2016).
13. Schloegel, M. J. et al. No evidence of locus heterogeneity in familial microcephaly with or without chorioretinopathy, lymphoedema, or mental retardation syndrome. *Orphanet. J. Rare Dis.* **10**, 52 (2015).
14. Ostergaard, P. et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphoedema and chorioretinopathy. *Am. J. Hum. Genet.* **90**(2), 356–362 (2012).
15. Hu, H. et al. KIF11 mutations are a common cause of autosomal dominant familial exudative vitreoretinopathy. *Br. J. Ophthalmol.* **100**(2), 275–283 (2016).
16. Robitaille, J. M. et al. Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphoedema, and chorioretinal dysplasia caused by KIF11 mutations. *JAMA Ophthalmol.* **132**(12), 1393–1399 (2014).
17. Wheway, G., Nazlamova, L. & Hancock, J. T. Signaling through the primary cilium. *Front. Cell Dev. Biol.* **6**, 8 (2018).
18. Reiter, J. F. & Leroux, M. R. Genes and molecular pathways underpinning ciliopathies. *Mol. Gen. Genet.* **280**(8), 533–547 (2017).
19. Birtel, J. et al. Novel insights into the phenotypical spectrum of KIF11-associated retinopathy, including a new form of retinal chorioretinopathy. *Invest. Ophthalmol. Vis. Sci.* **58**(10), 3950–3959 (2017).
20. Wheway, G., Parry, D. A. & Johnson, C. A. The role of primary cilia in the development and disease of the retina. *Organelloes* **10**(1), 69–85 (2014).
21. Sarksian, M. R. et al. Detection of primary cilia in human glioblastoma. *J. Neurooncol.* **117**(1), 15–24 (2014).
22. Moser, J. J., Fritschar, M. J. & Rattner, J. B. Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors. BMC Clin. Pathol. 14, 40 (2014).
23. Venkatesh, D. Primary cilia. J. Oral Maxillofac. Pathol. 21(1), 8–10 (2017).
24. Higginbotham, H. et al. Arl13b-regulated cilia activities are essential for polarized radial glial scaffold formation. Nat. Neurosci. 16(4), 1000–1007 (2013).
25. Breunig, J. J. et al. Primary cilia regulate hippocampal neurogenesis by mediating sonic hedgehog signaling. Proc. Natl. Acad. Sci. USA 105(35), 13127–13132 (2008).
26. Reilly, M. L. & Bennerhah, A. Ciliary kinesins beyond IFT: Cilium length, disassembly, cargo transport and signalling. Biol. Cell 111(4), 79–94 (2019).
27. van Dam, T. J. P. et al. CiliaCarta: an integrated and validated compendium of ciliary genes. PLoS ONE 14(5), e0216705 (2019).
28. Jia, R. et al. Spectrin-based membrane skeleton supports ciliogenesis. PLoS Biol. 17(7), e3000569 (2019).
29. Adams, M. et al. A meckelin-flamin A interaction mediates ciliogenesis. Hum. Mol. Genet. 21(6), 1272–1286 (2012).
30. Narita, K. et al. Proteomic analysis of multiple primary cilia reveals a novel mode of ciliary development in mammals. Biol. Open 1(8), 815–825 (2012).
31. Hong, H., Kim, J. & Kim, J. Myosin heavy chain 10 (MYH10) is required for centriole migration during the biogenesis of primary cilia. Biochem. Biophys. Res. Commun. 461(1), 180–185 (2015).
32. Rao, Y. et al. A Mec17-Myosin II effector axis coordinates microtubule acetylation and actin dynamics to control primary cilium biogenesis. PLoS ONE 9(12), e114087 (2014).
33. Ghossoon, R. et al. Septins 2, 7 and 9 and MAP4 colocalize along the axoneme in the primary cilium and control cilary length. J. Cell Sci. 126(Pt 12), 2583–2594 (2013).
34. Palander, O., El-Zeiry, M. & Trimble, W. S. Uncovering the roles of septins in cilia. Front. Cell Dev. Biol. 5, 36 (2017).
35. Chen, T. Y. et al. Cell cycle-dependent localization of dynactin subunit p150 glued at centrosome. J. Cell Biochem. 116(9), 2049–2060 (2015).
36. Gupta, G. D. et al. A dynamic protein interaction landscape of the human centrosome-cilium interface. Cell 163(6), 1484–1499 (2015).
37. Lancaster, M. A., Schroth, J. & Gleeson, J. G. Subcellular spatial regulation of canonical Wnt signaling at the primary cilium. Nat. Cell Biol. 13(6), 700–707 (2011).
38. May-Simera, H. L. & Kelley, M. W. Cilia, Wnt signaling, and the cytoskeleton. Cilia 1(1), 7 (2012).
39. Canterini, S. et al. Shortened primary cilium length and dysregulated sonic hedgehog signaling in Niemann-Pick C1 disease. Hum. Mol. Genet. 26(12), 2277–2289 (2017).
40. Broekhuis, J. R., Verhey, K. J. & Jansen, G. Regulation of cilium length and intratflagellar transport by the RCK-kinases ICK and MOK in renal epithelial cells. PLoS ONE 9(9), e108470 (2014).
41. Malvezzi, I. V. M. et al. KIF11 microdellion is associated with microcephaly, chorioretinopathy and intellectual disability. Hum. Genome Varitat. 5, 18010 (2018).
42. Valente, E. M. et al. Primary cilia in neurodevelopmental disorders. Nat. Rev. Neurosel. 10(1), 27–36 (2014).
43. Veland, L. et al. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol. 111(3), 39–53 (2009).
44. Funa, K. & Sasahara, M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J. Neuroimmun Pharmacol. 9(2), 168–181 (2014).
45. Charytoniuk, D. et al. Sonic Hedgehog signalling in the developing and adult brain. J. Physiol. Paris 96(1–2), 9–16 (2002).
46. Huangfu, D. et al. Hedgehog signalling in the mouse requires intratflagellar transport proteins. Nature 426(6962), 83–87 (2003).
47. Murdoch, J. N. & Copp, A. J. The relationship between sonic Hedgehog signaling, cilia, and neural tube defects. Birth Defects Res. A Clin. Mol. Teratol. 88(8), 633–652 (2010).
48. Goetz, S. C. & Anderson, K. V. The primary cilium: a signalling centre during vertebrate development. Nat. Rev. Genet. 11(5), 331–344 (2010).
49. Spasic, M. & Jacobs, C. R. Lengthening primary cilia enhances cellular mechanosensitivity. Eur. Cell Mater. 33, 158–168 (2017).
50. Lu, H. et al. A function for the Joubert syndrome protein Arl13b in cilary membrane extension and cilary length regulation. Dev. Biol. 397(2), 225–236 (2015).
51. Pejskova, P. et al. KIF14 controls ciliogenesis via regulation of Aurora A and is important for Hedgehog signaling. J. Cell Biol. https://doi.org/10.1083/jcb.201904107 (2020).
52. Wordeman, L. How kinesin motor proteins drive mitotic spindle function: Lessons from molecular assays. Semin. Cell Dev. Biol. 21(3), 260–268 (2010).
53. Verhey, K. J., Dissingher, J. & Kee, H. L. Kinesin motors and primary cilia. Eur. Cell Mater. 39(5), 1110–1125 (2011).
54. Majumder, S. & Fisk, H. A. VDAC3 and Mps1 negatively regulate ciliogenesis. Cell Cycle 12(5), 849–858 (2013).

Acknowledgements

The authors thank Dr. Jeremy Rich (UC San Diego) for the kind gift of the GBM 08-387 cells. The authors also thank Dr. Liwen Zhang of the Proteomics Shared Resource at The Ohio State Comprehensive Cancer Center and Dr. Belinda Willard of the Lerner Research Institute Mass Spectrometry Laboratory for Protein Sequencing at the Cleveland Clinic Foundation for sample processing and analysis. We also thank members of the Venere lab and Dr. Matthew Summers for insightful discussion and constructive comments on the manuscript. This work was supported by a Research Scholar Grant RSG-18-066-01-TBG from the American Cancer Society, the National Institutes of Health Grant R03CA227206, and funds from The Ohio State University Comprehensive Cancer Center/Department of Radiation Oncology (MV); and an Ohio State University Graduate School Dean’s Distinguished University Fellowship (AZ). The Fusion Lumos instrument from the Lerner Research Institute Mass Spectrometry Laboratory for Protein Sequencing at the Cleveland Clinic Foundation was purchased via a National Institutes of Health shared instrument Grant, 1S10OD023436-01. Research reported in the publication was supported by The Ohio State University Comprehensive Cancer Center and the National Institutes of Health under Grant Number P30 CA016058. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

M.V. supervised the study; M.V. and S.M. designed the study; M.V., A.Z., and S.M. designed experiments; A.Z., S.M., and K.D. performed experiments; M.V., A.Z., and S.M. analyzed data; A.Z. wrote the manuscript; all authors read, revised, and approved the final manuscript.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70787-4.
Correspondence and requests for materials should be addressed to M.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020